Skip to main content
. 2018 Jul 28;18(3):211–219. doi: 10.1007/s40268-018-0240-1

Table 5.

Biologic treatment history

Biologic DMARD usea f (%)
Total, n = 113
Any biologic 50 (44.2)
 Tocilizumab 22 (19.5)
 Certolizumab 5 (4.4)
 Etanercept 13 (11.5)
 Adalimumab 17 (15.0)
 Abatacept 21 (18.6)
 Rituximab 15 (13.3)

DMARD disease-modifying antirheumatic drug, f frequency or frequency of observations

aBiologics other than the study medications (infliximab and intravenous golimumab only)